abrdn Life Sciences Investors
HQL
Market Cap$409.44M
Close$
$0.00
0% upside
Current Fair Value
0% upsideOvervalued by 0% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $409.44 Million |
|---|---|
| Enterprise Value | $409.44 Million |
| Dividend Yield | $1.96 (11.0888443553774%) |
| Earnings per Share | $0.83 |
| Beta | 0.7 |
| Outstanding Shares | 27,350,516 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 6.4 |
|---|---|
| PEG | -1.58 |
| Price to Sales | 12.85 |
| Price to Book Ratio | 0.8 |
| Enterprise Value to Revenue | 9.97 |
| Enterprise Value to EBIT | 5.74 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-end fund that invests in public and private companies in the life sciences industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund.